title: Concordance with ASCO guidelines for surveillance after colorectal cancer treatment: a population-based analysis.
abstract: OBJECTIVE
  Intensive surveillance after curative treatment of colorectal cancer (CRC) is associated with improved overall survival. This study examined concordance with the 2005 ASCO surveillance guidelines at the population level.
  
  
  METHODS
  A cohort of 250 patients diagnosed with stage II or III CRC in 2004 and alive 42 months after diagnosis was identified from health administrative data in Manitoba, Canada. Colonoscopy, liver imaging, and carcinoembryonic antigen (CEA) testing were assessed over 3 years. Guidelines were met if patients had at least one colonoscopy in 3 years and at least one liver imaging test and three CEA tests annually. Multivariate logistic regression assessed the effect of patient and physician characteristics and disease and treatment factors on guideline concordance.
  
  
  RESULTS
  Guidelines for colonoscopy, liver imaging, and CEA were met by 80.4%, 47.2%, and 22% of patients, respectively. Guideline concordance for colonoscopy was predicted by annual contact with a surgeon, higher income, and the diagnosis of colon (rather than rectal) cancer. Adherence was lower in those older than 70 years and with higher comorbidity. For liver imaging, significant predictors were annual contact with an oncologist, receipt of chemotherapy, and diagnosis of colon cancer. Concordance with CEA guidelines was higher with annual contact with an oncologist and high levels of family physician contact, and lower in urban residents, in those older than 70, and in those with stage II disease.
  
  
  CONCLUSIONS
  Completion of recommended liver imaging and CEA testing fall well below guidelines in Manitoba, whereas colonoscopy is better provided. Addressing this gap should improve outcomes for CRC survivors.
authors.affiliation: University of Manitoba, Winnipeg, Manitoba, Canada. jeff.sisler@cancercare.mb.ca
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Sisler
authors.forename: Bosu
authors.initials: B
authors.lastname: Seo
authors.forename: Alan
authors.initials: A
authors.lastname: Katz
authors.forename: Emma
authors.initials: E
authors.lastname: Shu
authors.forename: Daniel
authors.initials: D
authors.lastname: Chateau
authors.forename: Piotr
authors.initials: P
authors.lastname: Czaykowski
authors.forename: Debrah
authors.initials: D
authors.lastname: Wirtzfeld
authors.forename: Harminder
authors.initials: H
authors.lastname: Singh
authors.forename: Donna
authors.initials: D
authors.lastname: Turner
authors.forename: Patricia
authors.initials: P
authors.lastname: Martens
mesh_terms: D000368:Aged; D002272:Carcinoembryonic Antigen / Q000097:blood; D015331:Cohort Studies; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D005260:Female; D019983:Guideline Adherence; D017408:Guidelines as Topic; D006801:Humans; D008099:Liver; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy; D010349:Patient Compliance; D011159:Population Surveillance; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D002272:Carcinoembryonic Antigen